Matthew J Wolf, MD, PhD

Associate Professor of Medicine (tenured)
Co-Director of the Cardiovascular Genetics Program
Resident faculty member of the Robert M. Berne Cardiovascular Research Center
Joint Appointment, Department of Molecular Physiology and Biological Physics, University of Virginia

See more at:

CVRC LAB

Center at UVA focuses on developing new therapeutics to treat cardiovascular diseases. We aim to understand better the signals mediating cardiomyocyte growth, hypertrophy, and heart failure. The mammalian heart has little ability to generate new cardiomyocytes after injury, and identifying cycling cells is challenging. We develop sophisticated transgenic mice to label and genetically manipulate adult cycling cardiomyocytes and use a variety of disease models to investigate cardiac regeneration. Our work has identified new therapeutics that improve myocardial function after injury. Additionally, we use cardiac MRI to investigate the mechanisms causing microvascular coronary disease and impaired myocardial perfusion reserve in models of diet-induced obesity.

Role of iNOS in preventing and reversing coronary microvascular disease due to a high-fat, high-sucrose diet.

Inhibition of DYRK 1a Enhances Cardiomyocyte Cycling after Myocardial Infarction.

Loss of Endogenously Cycling Adult Cardiomyocytes Worsens Myocardial Function.

AHA Scientific Statement Heart Failure in the Era of Precision Medicine. A Scientific Statement from the American Heart Association, Circulation: Genomics and Precision Medicine.

Cardiac hypertrophy induced by active Raf depends on Yorkie-mediated transcription.